发明授权
- 专利标题： 1,4 oxazines as BACE1 and/or BACE2 inhibitors
- 专利标题（中）： 1,4个恶嗪作为BACE1和/或BACE2抑制剂
-
申请号： US13357640申请日： 2012-01-25
-
公开(公告)号： US08399459B2公开(公告)日： 2013-03-19
- 发明人: Matteo Andreini , Emanuele Gabellieri , Robert Narquizian , Massimiliano Travagli , Wolfgang Wostl
- 申请人： Matteo Andreini , Emanuele Gabellieri , Robert Narquizian , Massimiliano Travagli , Wolfgang Wostl
- 申请人地址： US NJ Nutley IT Siena
- 专利权人： Hoffmann-La Roche Inc.,Siena Biotech SpA
- 当前专利权人： Hoffmann-La Roche Inc.,Siena Biotech SpA
- 当前专利权人地址： US NJ Nutley IT Siena
- 代理商 George W. Johnston; Patricia S. Rocha-Tramaloni; Kimberly J. Prior
- 优先权： EP11153095 20110202
- 主分类号： A61K31/535
- IPC分类号： A61K31/535 ; C07D265/28
摘要：
The present invention provides 1,4 Oxazines of formula I having BACE1 and/or BACE2 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease and type 2 diabetes.
公开/授权文献
- US20120196863A1 1,4 OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS 公开/授权日：2012-08-02
信息查询
